Thetis Pharmaceuticals LLC is a
pre-clinical pharmaceutical company focused on type 2 diabetes and
related chronic conditions. Its lead asset (TP101) is a new molecular
entity being developed for first-line oral anti-diabetic therapy.
The pharmacologic agents that comprise TP101 have extensive
clinical safety and efficacy data and excellent safety profiles that
provide the foundation for a potentially expedited regulatory pathway
for approval in the USA and other major markets.
Thetis is initiating discussions with potential development
partners. The company is operating on funds provided by
private investors.
